Diagnostic and therapeutic management of cancer of an unknown primary

European Journal of Cancer

Volumn 39, Issue 14, 2003, Pages 1990-2005

  Pavlidis, N ^a   Briasoulis, E ^a   Hainsworth, J ^b   Greco, F A ^b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b CENTENNIAL MEDICAL CENTER   (United States)

Author keywords

Cancer; Diagnosis; Metastasis; Treatment; Unknown origin; Unknown primary

Indexed keywords

ALPHA INTERFERON; ALTRETAMINE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN C; NITROSOUREA DERIVATIVE; PACLITAXEL; PENTETREOTIDE IN 111; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; VINBLASTINE; VINCRISTINE;

ADENOCARCINOMA; AUTOPSY; AXILLARY LYMPH NODE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER OF UNKNOWN PRIMARY; CARCINOMATOUS PERITONITIS; CERVICAL LYMPH NODE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; ELECTRON MICROSCOPY; ENDOSCOPY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INGUINAL LYMPH NODE; LIVER METASTASIS; LUNG CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MAMMOGRAPHY; MELANOMA; METASTASIS; MICROSCOPY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CARCINOMA; PARAAORTIC LYMPH NODE; PERITONEUM METASTASIS; PLEURA EFFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA; THORAX RADIOGRAPHY; TUMOR DIFFERENTIATION; DIAGNOSTIC IMAGING; FEMALE; MALE; METHODOLOGY; NEOPLASM; PHYSICIAN ATTITUDE; PROSPECTIVE STUDY;

DIAGNOSTIC IMAGING; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASMS, UNKNOWN PRIMARY; PHYSICIAN'S ROLE; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 0037905503     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00547-1     Document Type: Article

References (119)

1. Ries L.A.G., Eisner M.P., Kosary C.L.et al. SEER Cancer Statistics Review. 1999;National Cancer Institute, Bethesda.
2. Levi F., Te V.C., Erler G., Randimbison L., La Vecchia C. Epidemiology of unknown primary tumors. Eur. J. Cancer. 38:2002;1810-1812.
3. van de Wouw A.J., Janssen-Heijnen M.L.G., Coebergh J.W.W., Hillen H.F. Epidemiology of unknown primary tumors; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur. J. Cancer. 38:2002;409-413.
4. Jordan III W.E., Shildt R.A. Adenocarcinoma of unknown primary site. The Brooke Army Medical Center experience. Cancer. 55:1985;857-860.
5. Galifano J., Westra W.H., Koch W.et al. Unknown primary head and neck squamous cell carcinoma. molecular identification of the site of origin J. Natl. Cancer Inst. 91:1999;599-604.
6. Holmes F.F., Fouts T.L. Metastatic cancer of unknown primary site. Cancer. 26:1970;816-820.
7. Frost P., Raber M.N., Abbruzzese J.L. Unknown primary tumors as a unique clinical and biologic entity. a hypotheis Cancer Bull. 41:1989;139-141.
8. Abbruzzese J.L., Abbruzzese M.C., Lenzi R., Hess K.R., Raber M.N. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J. Clin. Oncol. 13:1995;2094-2103.
9. Greco F.A., Hainsworth J.D. Cancer of unknown primary site. DeVita T.V., Hellman S., Rosenberg S.A. Cancer: Principles and Practice of Oncology. 4th edn. 1997;2423-2443 J.B. Lippincott Co, Philadelphia.
10. Silverberg E., Luber J. Cancer Statistics. 37:1987;2-19.
11. Muir C. Cancer of unknown primary site. Cancer. 75:1995;353-356.
12. Coates M., Armstrong B. NSW Central Cancer Registry. Cancer in New South Wales. Incidence and Mortality. 1995;Cancer Council, NSW.
13. Visser O., Coebergh J.W.W., Schouten L.J. Incidence of Cancer in the Netherlands 1993. 1993;The Netherlands Cancer Registry, Utrecht.
14. Parkin D.M., Muir C.S., Whelan S.L.et al. Cancer Incidence in Five Continents, Vol VI. IARC Scientific Publication No. 120. 1992;IARC, Lyon.
15. Neumann G. The impact of cancer with unspecified site. Off Gesundheitswes. 50:1988;13-19.
16. Komov D.V., Komarov I.G., Podrguliskii K.R.et al. Cancer metastases from an unestablished primary tumor (clinical aspects, diagnosis, treatment). Sov. Med. Rev. F. Oncology. 4:1991;1-33.
17. Parkin D.M., Whelan S.L., Ferlay J., Raymond L., Young J. Cancer Incidence in Five Continents, vol VII. IARC No 143. 1991;IARC, Lyon.
18. Nystrom J.S., Weiner J.M., Hellelfinger-Juttner J., Irwin L.E., Bateman J.R., Wolf R.M. Metastatic and histologic presentation in unknown primary cancer. Semin. Oncol. 4:1977;53-58.
19. Briasoulis E., Pavlidis N. Cancer of unknown primary origin. Oncologist. 2:1997;142-152.
20. Abbruzzese J.L., Abbruzzese M.C., Hess K.R., Raber M.N., Lenzi R., Frost P. Unknown primary carcinoma. natural history and prognostic factors in 657 consecutive patients J. Clin. Oncol. 12:1994;1272-1280.
21. Ayoub J.P., Hess K.R., Abbruzzese M.C., Lenzi R., Raber M.N., Abbruzzese J.C. Unknown primary tumors metastatic to liver. J. Clin. Oncol. 16:1998;2105-2112.
22. Richardson R.L., Greco F.A., Wolff S.et al. Extragonadal germ cell malignancy. value of tumor markers in metastatic carcinoma in young men Proc. Am. Soc. Clin. Oncol. 20:1979;204.
23. Fox R.M., Woods R.L., Tattersall M.H.N., McGovern V.J. Undifferentiated carcinoma in young men. the atypical teratoma syndrome Lancet. i:1979;1316-1318.
24. Richardson R.L., Schoumacher R., Oldham R.K.et al. The unrecognized extragonadal germ cell syndrome. Ann. Intern. Med. 94:1981;181-189.
25. Greco F.A., Vaughn W.K., Hainsworth J.D. Advanced poorly differentiated carcinoma of unknown primary site. recognition of a treatable syndrome Ann. Intern. Med. 142:1986;547-553.
26. Hainsworth J.D., Wright E.P., Gray G.F., Greco F.A. Poorly differentiated carcinoma of unknown primary site. correlation of light microscopic findings with response to cisplatin-based combination chemotherapy J. Clin. Oncol. 5:1987;1275-1280.
27. Hainsworth J.D., Johnson D.H., Greco F.A. Poorly differentiated neuroendocrine carcinoma of unknown primary site. a newly recognized clinicopathologic entity Ann. Intern. Med. 109:1988;364-371.
28. Van der Gaast A., Verweij J., Henzen-Logmans S.C.et al. Carcinoma of unknown primary. identification of a treatable subset Ann. Oncol. 1:1990;119-122.
29. Ellerbroek N., Holmes F., Singletary E., Evans H., Oswald M., McNeese M. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer. 66:1990;1461-1467.
30. Foroudi F., Tiver K.W. Occult breast carcinoma presenting as axillary metastases. Int. J. Radiat. Oncol. Biol. Phys. 47:2000;143-147.
31. Vlastos G., Jean M.E., Mizza A.N.et al. Feasibility of breast presentation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann. Surg. Oncol. 8:2001;425-431.
32. Jackson B., Scott-Conner C., Moulder J. Axillary metastases from occult breast carcinoma. diagnosis and management Am. Surg. 61:1995;431-434.
33. Grau C., Johansen L.V., Jakobsen J., Geertsen P., Andersen E., Jensen B.B. Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother. Oncol. 55:2000;121-129.
34. Nieder C., Gregoire V., Ang K.K. Cervical lymph node metastases from occult squamous cell carcinoma. cut down a tree to get an apple? Int. J. Radiat. Oncol. Biol. Phys. 50:2001;727-733.
35. Guarischi A., Keane T.J., Elhakim T. Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases. Cancer. 19:1987;572-577.
36. Casciato D.A., Tabbarah H.J. Metastases on unknown origin. Haskell C.M. Cancer Treatment. 3rd edn. 1990;798-814 WB Saunders, Philadelphia.
37. Chen K.T., Flam M.S. Peritoneal papillary serous carcinoma with long-term survival. Cancer. 58:1986;1371-1373.
38. Dalrymple J.C., Bannatyne P., Russel P.et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer. 64:1989;110-115.
39. Ransom D.T., Patel S.R., Keeney G.L., Malkasian G.D., Edmonson J.H. Papillary serous carcinoma of the peritoneum. Cancer. 66:1990;1091-1094.
40. Chu D.Z., Lang N.P., Thompson C., Osteen P.K., Westbrook K.C. Peritoneal carcinomatosis in nongynecologic malignancy. Cancer. 63:1989;364-367.
41. Tell D.T., Khoury J.M., Taylor H.G., Veasey S.P. Atypical metastasis from prostate cancer. clinical utility of the immunoperoxidase technique for prostate specific antigen JAMA. 253:1985;3574-3579.
42. Gentile P.S., Carloss H.W., Huang T.-Y., Yam L.T., Lam W.K. Disseminated prostatic carcinoma simulating primary lung cancer. Cancer. 62:1988;711-714.
43. Le Chevalier T., Smith F.P., Caille P., Costans J.P., Rouesse J.G. Sites of primary malignancies in patients presenting with cerebral metastases. A review of 120 cases. Cancer. 56:1985;880-882.
44. Nguyen L.N., Maor M.H., Oswald M.J. Brain metastases as the only manifestation of an undetected primary tumor. Cancer. 83:1998;2181-2184.
45. Wen P.Y., Loeffler J.S. Management of brain metastases. Oncology. 13:1999;941-954.
46. Moertel C.G., Kvols L.K., O' Connell M.J., Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. evidence of major therapeutic activity in the anaplastic variants of these neoplasms Cancer. 68:1991;227-233.
47. Das Gupta T., Bowden L., Berg J.W. Malignant melanoma of unknown primary origin. Surg. Gynecol. Obst. 117:1963;341-345.
48. Chang P., Knapper W.H. Metastatic melanoma of unknown primary. Cancer. 49:1982;1106-1111.
49. Schlagenhauff B., Stroebel W., Ellwanger U.et al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma. Cancer. 80:1997;60-65.
50. Bar-Eli M., Abbruzzese J.L., Lee-Jackson D., Frost F. p53 gene mutation spectrum in human unknown primary tumors. Anticancer Res. 13:1993;1619-1624.
51. Briasoulis E., Tsokos M., Fountzilas G.et al. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin. biological and clinical implications. A Hellenic Co-operative Oncology Group Study Anticancer Res. 18:1998;1907-1914.
52. Pavlidis N., Briasoulis E., Bai M., Fountzilas G., Agnantis N. Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. Anticancer Res. 15:1995;2563-2567.
53. Hainsworth J.D., Lennington W.J., Greco F.A. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J. Clin. Oncol. 18:2000;632-635.
54. Karavasilis V, Tsanou E, Malamou-Mitsi V, et al. Microvessel density and vascular endothelial growth factor in cancer of unknown primary. An immunohistochemical study. Proc ESMO, 2002, 51p.
55. Mackey B., Ordonez N.G. Pathological evaluation of neoplasm with unknown primary tumor site. Semin. Oncol. 20:1993;206-228.
56. Tot T. Adenocarcinoma metastatic to the liver. the value of cytokeratins 20 and 7 in the search for unknown primary tumors Cancer. 85:1999;171-177.
57. Tot T. Cytokeratins 20 and 7 as biomarkers. usefuleness in discriminating primary from metastatic adenocarcinoma Eur J Cancer. 38:2002;758-763.
58. Motzer R.J., Rodriguer E., Reuter V.E., Bosl G.J., Mazumdar M. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J. Clin. Oncol. 13:1995;274-282.
59. Atkin N.B., Baker M.C. Specific chromosome change, i(12p) in testicular tumors. Lancet. 1982;1349-1356.
60. Ilson D.H., Motzer R.J., Rodriguez E., Chaganti R.S.K., Bosl G.J. Genetic analysis in the diagnosis of neoplasm of unknown primary tumor site. Semin. Oncol. 20:1993;229-237.
61. Le Chevalier T., Cvitkovic E., Caille P.et al. Early metastatic cancer of unknown origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch. Intern. Med. 148:1988;2035-2039.
62. Nystrom S., Weiner J., Wolf R.M., Bateman J.R., Viola M.V. Identifying the primary site in metastatic cancer of unknown origin. Inadequacy of roentgenographic procedures. JAMA. 241:1979;381-383.
63. Stewart J., Tattersall M., Woods R., Fox R. Unknown primary adenocarcinoma. incidence of overinvestigation and natural history Br. Med. J. 1:1979;1530-1533.
64. Karsell P.R., Sheedy P.F., O'Connell M.J. Computed tomography in search of cancer of unknown origin. JAMA. 248:1982;340-343.
65. McMillan J.H., Levine E., Stephens R.H. Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site. A retrospective study. Radiology. 143:1982;143-146.
66. Baron P.L., Moore M.P., Kinne D.W.et al. Occult breast cancer presenting with axillary metastases. Updated management. Arch. Surg. 125:1990;210-214.
67. Orel S.G., Weinstein S.P., Schnall M.D.et al. Breast MR Imaging in patients with axillary node metastases and unknown primary malignancy. Radiology. 212:1999;543-549.
68. Lassen U., Daugaard G., Eigtved A., Damgaard K., Friberg L. 18F-FDG whole body position emission tomography (PET) in patients with unknown primary tumors (UPT). Eur. J. Cancer. 35:1999;1076-1082.
69. Bohuslavizki K.H., Klutmann S., Kroger S.et al. FDG PET detection of unknown primary tumors. J. Nucl. Med. 41:2000;816-822.
70. Jungehulsing M., Scheidhauer K., Damm M.et al. 2[F]-Fluoro-2-deoxy-D- glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg. 123:2000;294-301.
71. Lonneux M., Reffad A. Metastases from unknown primary tumor. PET-FDG as initial diagnostic procedure? Clin Positron Imag. 3:2000;137-141.
72. Rades D., Kuhnel G., Wildfang I., Borner A.R., Schmoll H.J., Knapp W. Localised disease in cancer of unknown primary (CUP). the value of positron emission tomography (PET) for individual therapeutic management Ann. Oncol. 12:2001;1605-1609.
73. Lenzi R., Kim E.E., Raber M.N., Abbruzzese J.L. Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111In-pentetreotide scan. Ann. Oncol. 9:1998;213-216.
74. Milovic M., Popov I., Jelic S. Tumor markers in metastatic disease from cancer of unknown primary origin. Med. Sci. Monit. 8:2002;MT25-MT30.
75. Pavlidis N., Kalef-Ezra J., Briasoulis E.et al. Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med. Pediatr. Oncol. 22:1994;162-167.
76. Panza N., Lombardi G., De Rosa M., Pacilio G., Lapenta L., Salvatore M. High serum thyroglobulin levels. Diagnostic indicators in patients with metastases from unknown primary sites. Cancer. 60:1987;2233-2236.
77. Shahangian S., Fritsche H.A. Serum tumor markers as diagnostic aids in patients with unknown primary tumors. Cancer Bull. 41:1989;152-156.
78. Abbruzzese J.L., Raber M.N., Frost P. The role of CA 125 in patients with unknown primary tumors. Proc. Am. Soc. Clin. Oncol. 10:1991;39.
79. Smith P., Krementz E., Chapman W. Metastatic cancer without a detectable primary site. Am. J. Surg. 113:1967;633-637.
80. Probert J. Secondary carcinoma in cervical lymph nodes with an occult primary tumor. A review of 61 patients including their response to radiotherapy. Clin. Radiol. 21:1970;211-218.
81. Pico J., Frias Z., Bosch A. Cervical lymph node metastases from carcinoma of undetermined origin. Am. J. Roentgenol. 111:1971;95-102.
82. Lleander V., Goldstein G., Horsley J. Chemotherapy in the management of metastatic cancer of unknown primary site. Oncology. 26:1972;265-270.
83. Moertel C., Reitemeier R., Schutt A.et al. Treatment of the patient with adenocarcinoma of unknown origin. Cancer. 30:1972;1469-1472.
84. Didolkar M., Fanous N., Elias E.et al. Metastatic carcinomas from occult primary tumours. A study of 254 patients. Ann. Surg. 186:1977;625-630.
85. Snyder R., Mavligit G., Valdivieso M. Adenocarcinoma of unknown primary site. a clinicopathological study Med. Pediatr. Oncol. 6:1979;289-294.
86. Steckel R., Kagan R. Diagnostic persistence in working-up metastatic cancer with an unknown primary site. Radiology. 134:1980;367-369.
87. Shildt R., Kennedy P., Chen T.et al. Management of patients with metastatic adenocarcinoma of unknown origin. a Southwest Oncology Group Study Cancer Treat. Rep. 67:1983;77-79.
88. Pasterz R., Savoraj N., Burgess M. Prognostic factors in metastatic carcinoma of unknown primary. J. Clin. Oncol. 4:1986;1652-1657.
89. Pavlidis N., Kosmidis P., Skarlos D.et al. Subsets of tumors responsive to cisplatin or carcboplatin combination in patients with carcinoma of unknown primary site. Ann. Oncol. 3:1992;631-634.
90. Greco F.A., Haisworth J.D. Poorly differentiated carcinoma or adenocarcinoma of unknown primary site. long-term results with cisplatin-based chemotherapy Semin. Oncol. 21(Suppl. 12):1994;77-82.
91. Briasoulis E., Tsavaris N., Fountzilas G.et al. Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site. a Hellenic Co-operative Oncology Group Phase II study Oncol. 55:1998;426-430.
92. Greco F.A., Hainsworth J.D. The evolving role of paclitaxel for patients with carcinoma of unknown primary site. Semin. Oncol. 26(Suppl. 12):1999;129-133.
93. Greco F.A., Erland J.B., Morrissey L.H.et al. Carcinoma of unknown primary site. phase II trials with docetaxel plus cisplatin or carboplatin Ann. Oncol. 11:2000;211-215.
94. Greco F.A., Burris H.A., Erland E.B.et al. Carcinoma of unknown primary site. Long term follow-up after treatment with paclitaxel, carboplatin and etoposide. Cancer. 89:2000;2655-2660.
95. Briasoulis E., Kalofonos H., Bafaloukos D.et al. Carboplatin plus paclitaxel in unknown primary carcinoma. a phase II study. The Hellenic Cooperative Oncology Group Study J. Clin. Oncol. 18:2000;3101-3117.
96. Greco F.A., Gray J., Burris H.A.et al. Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J. 7:2001;203-212.
97. Voog E., Merrouche Y., Trillet-Lenoir V.et al. Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary. Am. J. Clin. Oncol. 23:2000;614-616.
98. Culine S., Ychou M., Fabbro M., Romieu G., Cupissol D. 5-fluorouracil and leucovorin as second line chemotherapy in carcinomas of unknown primary site. Anticancer Res. 21:2001;1455-1457.
99. Hainsworth J.D., Burris 3rd H.A., Calvert S.W.et al. Gemcitabine in the second- line therapy of patients with carcinoma of unknown primary site. a phase II trial of the Minnie Pearl Cancer Research Network Cancer Invest. 19:2001;335-339.
100. Culine S., Fabbro M., Ychou M., Romieu G., Cupissol D., Rujol H. Chemotherapy in carcinomas of unknown primary site. a high-dose intensity policy Ann. Oncol. 10:1999;569-575.
101. Jadeja J., Legha S., Burgess M.et al. Combination chemotherapy with 5-fluorouracil, adriamycin, cyclophosphamide, and cis-platinum in the treatment of adenocarcinoma of unknown primary and undifferentiated carcinomas. Proc. Am. Soc. Clin. Oncol. 1983;926. (abstr).
102. Milliken S.T., Tattershall M.H.L., Woods R.L.et al. Metastatic adenocarcinoma of unknown primary site. a randomized study of two combination chemotherapy regimens Eur. J. Cancer Clin. Oncol. 23:1987;1645-1648.
103. Becouarn Y., Brunet R., Barbe-Gaston C. Fluorouracil, doxorubicin, cisplatin and altretanine in the treatment of metastatic carcinoma of unknown primary. Eur. J. Cancer Clin. Oncol. 25:1989;861-868.
104. Raber M.N., Faintuch J., Abbruzzese L.J.et al. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. Ann. Oncol. 2:1991;519-520.
105. Lenzi R., Abbruzzese J., Amato R.et al. Cisplatin, 5-fluorouracil and follinic acid for the treatment of carcinoma of unknown primary. a phase II study Proc. Am. Soc. Clin. Oncol. 10:1991;301. (abstr).
106. Gill I., Guaglianone P., Grunberg S.M.et al. High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary. Anticancer Res. 11:1991;123-1235.
107. Wagener D.J.T., de Muelder P.H.M., Burghouts J.T.et al. Phase II trial of cisplatin in adenocarcinoma of unknown primary site. Eur. J. Cancer. 27:1991;755-760.
108. Falkson C.I., Cohen G.L. Mitomycin, epirubicin and cisplatin versus mitomycin-C alone as therapy for carcinoma of unknown primary origin. Oncology. 55:1998;116-121.
109. Warner E., Goel R., Chang J.et al. A multicenter phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). Br. J. Cancer. 77:1998;2376-2380.
110. Lofts F.J., Gogas H., Mansi J.L. Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy regimen (CFT arm). Ann. Oncol. 10:1999;1389-1392.
111. Guardiola E., Pivot X., Tchicknavorian X.et al. Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site. a phase II trial Am. J. Clin. Oncol. 24:2001;372-375.
112. Saghatchian M., Fizazi K., Borel C.et al. Carcinoma of an unknown primary site. a chemotherapy strategy based on histogical differentiation- results of a prospective study Ann. Oncol. 12:2001;535-540.
113. Macdonald A.G., Nicolson M.C., Samuel L.M.et al. A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (UCF) in the treatment of patients with carcinoma of unknown primary site. Br. J. Cancer. 86:2002;1238-1242.
114. Lortholary A., Culine S., Bouzy J.et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary. results of a randomized phase II study Proc. Am. Soc. Clin. Oncol. 153a:2002;609.
115. Dowell J., Garrett A.M., Shyr Y., Johnson D.H., Hande K.R. A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer. 91:2001;592-597.
116. Greco F.A., Burris III H.A., Litchy S.et al. Gemcitabine, carboplatin and paclitaxel for patients with carcinoma of unknown primary site. a Minnie Pearl Cancer Research Network study J. Clin. Oncol. 20:2002;1651-1656.
117. Gothelf A., Daugaard G., Nelausen K. Paclitaxel, cisplatin and gemcitabine in the treatment of unknown primary tumours, a phase II study. Proc ESMO. 25:2002;88.
118. Bouleuc C., Saghatchian M., Di Tullio L.et al. A multicenter phase II study of docetaxel and cisplatin in the treatment of cancer of unknown primary site. Proc. Am. Soc. Clin. Oncol. 137b:2001;2298.
119. Darby A.J., Richardson L., Nokes L., Harvey M., Hassan A., Iveson T. Phase II study of single agent docetaxel in carcinoma of unknown primary site. Proc. Am. Soc. Clin. Oncol. 100b:2001;2151.